Adjuvant therapy for colorectal cancer: Yesterday, today, and tomorrow - The Beaven/Goldberg article reviewed

被引：0
作者：
Hewitt, Maureen R. [1 ]
Haller, Daniel G. [1 ]
机构：
[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA
来源：
ONCOLOGY-NEW YORK | 2006年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：473 / 475
页数：3
相关论文
共 10 条
  • [1] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    Andre, T
    Boni, C
    Mounedji-Boudiaf, L
    Navarro, M
    Tabernero, J
    Hickish, T
    Topham, C
    Zaninelli, M
    Clingan, P
    Bridgewater, J
    Tabah-Fisch, I
    de Gramont, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) : 2343 - 2351
  • [2] Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes
    Berger, AC
    Sigurdson, ER
    LeVoyer, T
    Hanlon, A
    Mayer, RJ
    Macdonald, JS
    Catalano, PJ
    Haller, DG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) : 8706 - 8712
  • [3] DEGRAMONT A, 2005, AM SOC CLIN ONC 2005
  • [4] Annual report to the Nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment
    Edwards, BK
    Brown, ML
    Wingo, PA
    Howe, HL
    Ward, E
    Ries, LAG
    Schrag, D
    Jamison, PM
    Jemal, A
    Wu, XC
    Friedman, C
    Harlan, L
    Warren, J
    Anderson, RN
    Pickle, LW
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (19): : 1407 - 1427
  • [5] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Hurwitz, H
    Fehrenbacher, L
    Novotny, W
    Cartwright, T
    Hainsworth, J
    Heim, W
    Berlin, J
    Baron, A
    Griffing, S
    Holmgren, E
    Ferrara, N
    Fyfe, G
    Rogers, B
    Ross, R
    Kabbinavar, F
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) : 2335 - 2342
  • [6] Colon cancer survival rates with the new American Joint Committee on cancer sixth edition staging
    O'Connell, JB
    Maggard, MA
    Ko, CY
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (19): : 1420 - 1425
  • [7] Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
    Saltz, LB
    Meropol, NJ
    Loehrer, PJ
    Needle, MN
    Kopit, J
    Mayer, RJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) : 1201 - 1208
  • [8] Fluorouracil in colorectal cancer a tale of two drugs: Implications for biochemical modulation
    Sobrero, AF
    Aschele, C
    Bertino, JR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) : 368 - 381
  • [9] OPTIMOX1:: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer -: A GERCOR study
    Tournigand, C
    Cervantes, A
    Figer, A
    Lledo, G
    Flesch, M
    Buyse, M
    Mineur, L
    Carola, E
    Etienne, PL
    Rivera, F
    Chirivella, I
    Perez-Staub, N
    Louvet, C
    André, T
    Tabah-Fisch, I
    de Gramont, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) : 394 - 400
  • [10] Wolmark N, 2005, J CLIN ONCOL, V23, p1092S
1